Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $6.36B
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.89
• Shares Outstanding: 75,573,510
• 10 Day Avg. Volume: 1,147,877
• 30 Day Avg. Volume: 1,133,471
• PEG Ratio: 0.14
• Price to Book (P/B): 10.98
• Price to Sales (P/S): 41.30
• P/FCF Ratio: -2.88
• Enterprise Value/Market Cap: 0.08
• Enterprise Value/Revenue: 54.49
• Enterprise Value/Gross Profit: 54.49
• Enterprise Value/Ebitda: -2.27
• 1Y Price Target: $106.17
• Price Target Upside: 26.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 49 Neutral
• Price Target: $68.00 ▼(-19.06% Downside)

Abivax SA's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.

Positive Factors

Innovative Product Pipeline

Abivax's focus on developing novel treatments for inflammatory diseases and viral infections positions it well in the biotech industry, potentially leading to breakthrough therapies and partnerships.

Revenue Growth Potential

While not yet commercial, Abivax's ability to secure funding and partnerships indicates strong potential for future revenue growth as clinical trials progress.

Strategic Focus on Unmet Needs

Targeting unmet medical needs can lead to high demand for successful products, offering Abivax a competitive advantage and potential for substantial market impact.

Negative Factors

High Operational Losses

Persistent operational losses and negative cash flows highlight financial instability, which could hinder long-term growth and sustainability without strategic improvements.

High Leverage

High leverage and negative return on equity suggest financial risk, potentially limiting Abivax's ability to invest in growth opportunities and manage economic downturns.

Negative Profit Margins

Negative profit margins indicate ongoing operational challenges, which could impede Abivax's ability to achieve profitability and sustain long-term financial health.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

Abivax SA is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for inflammatory diseases and viral infections, including its lead product candidate ABX464, which is being investigated for the treatment of ulcerative colitis and other indications. The company operates primarily in the biotechnology sector, leveraging its proprietary technologies to discover and develop innovative therapies that address significant unmet medical needs.

How the Company Makes Money

Abivax generates revenue primarily through funding from investors and partnerships in the biopharmaceutical industry. The company does not currently have commercial revenue from product sales, as it is still in the clinical development phase. Its revenue model is primarily reliant on securing grants, collaborations, and potential licensing agreements with larger pharmaceutical companies. Successful clinical trial outcomes can lead to milestone payments and royalties from partnerships, which can significantly contribute to its financial resources as it progresses towards commercialization.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While revenue is growing, profitability remains a concern with high operating losses and negative cash flows. These factors underscore the need for strategic improvements to enhance financial stability.

Income Statement

The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.

Cash Flow

Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.42M	10.79M	4.62M	4.58M	37.00K	63.00K
Gross Profit	9.42M	10.79M	4.57M	4.47M	-119.00K	-33.77M
EBITDA	-225.56M	-171.88M	-133.21M	-53.31M	-38.59M	-38.00M
Net Income	-195.39M	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	119.64M	205.23M	327.06M	75.54M	109.23M	71.30M
Cash, Cash Equivalents and Short-Term Investments	60.95M	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	98.71M	97.36M	55.46M	49.23M	51.65M	33.99M
Total Liabilities	167.92M	164.64M	131.05M	68.36M	83.30M	53.40M
Stockholders Equity	-48.28M	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-135.98M	-154.72M	-100.28M	-54.26M	-47.30M	-30.72M
Operating Cash Flow	-135.51M	-154.07M	-100.01M	-53.94M	-45.66M	-29.82M
Investing Cash Flow	2.42M	15.76M	-10.49M	-12.03M	-1.46M	-575.00K
Financing Cash Flow	-28.72M	28.21M	340.57M	32.21M	78.51M	49.93M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 84.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 84.01 is above the 20-day moving average (MA) of 80.42, above the 50-day MA of 58.26, and above the 200-day MA of 19.74, indicating a bullish trend. The MACD of 7.57 indicates Positive momentum. The RSI at 67.94 is Neutral, neither overbought nor oversold. The STOCH value of 47.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
ABVX	49 Neutral	$6.36B	―	-147.48%	―	―	18.47%
CELC	44 Neutral	$2.44B	―	-134.54%	―	―	-25.61%
ALMS	43 Neutral	$453.72M	―	-66.35%	―	―	-25.20%
ORIC	43 Neutral	$1.05B	―	-43.82%	―	―	-7.33%
AUTL	41 Neutral	$380.58M	―	-52.18%	―	187.52%	26.32%
ERAS	34 Underperform	$456.71M	―	-31.16%	―	―	50.77%

Abivax SA Sponsored ADR Corporate Events

Abivax Reports Increased Losses but Secures Major Funding in H1 2025

On September 8, 2025, Abivax SA announced its financial results for the first half of 2025, revealing a significant increase in operating loss to EUR 93.7 million compared to the same period in 2024. The increase was driven by higher research and development expenses, particularly related to the company’s Crohn’s Disease clinical program and the expansion of its R&D team. Despite a decrease in sales and marketing expenses, the company’s net financial position deteriorated, with a cash position of EUR 60.9 million as of June 30, 2025, down from EUR 144.2 million at the end of 2024. However, Abivax successfully completed a public offering in July 2025, raising approximately EUR 597.2 million in net proceeds, which is expected to support its ongoing clinical programs and operational goals.

Abivax SA Announces $608.6 Million Public Offering of ADSs

On July 23, 2025, Abivax SA entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co., and Guggenheim Securities, LLC for a public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per share. The offering is expected to generate approximately $608.6 million in net proceeds, with the closing anticipated on July 28, 2025. This move is part of Abivax’s strategy to strengthen its financial position and support its ongoing research and development efforts, potentially enhancing its market presence and stakeholder value.

Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment

On July 22, 2025, Abivax SA announced positive results from its Phase 3 ABTECT-1 and ABTECT-2 8-week induction trials for obefazimod, a first-in-class oral miR-124 enhancer, in treating moderate to severely active ulcerative colitis. The trials demonstrated that the 50 mg once-daily dose of obefazimod met the FDA primary endpoint of clinical remission at Week 8, with significant placebo-adjusted remission rates and favorable tolerability. These results reinforce obefazimod’s potential as a transformative treatment option for ulcerative colitis, especially for patients with inadequate responses to previous therapies.